Analysis of the cost- effectivenes of novel antiandrogens treatment of nonmetastatic castrate-resistant prostate cancer (nmCRPC)

Best Practice Nordic | Jun 2020 | ASCO20 Virtual |

Three new therapeutic agents for the treatment of nonmetastatic castrate-resistant prostate cancer (nmCRPC), apalutamid, darolutamid and enzalutamid, have recently been FDA approved. Not alone are the therapies new, they also open up to the treatment of a whole new group of patients, for whom there was no treatment possibility earlier. It raises several questions. On one side are the clinical, with regards to the effect, boundaries and identification of the patient group, as well as consequences for the sequential treatment possibilities as the disease progresses and side-effects. On the other side, there are the healthcare economic aspects, which were uncovered in an American study published at Asco. In this non-sponsored cost-efficiency analysis, the parameters metastasis free survival, metastatic disease and death were evaluated based on the perspectives of the American healthcare system. The results of the analysis were presented both in relation to survival and the QUALY-value. The three therapies were estimated with different QUALY-values between 5,30 and 3,05. Read the original abstract published at Asco here